Cryoport Inc logo

Cryoport Inc(CYRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 59 days
PROFIT SINCE LAST BUY
+21.73% ▲
LAST CLOSE
$19.89
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CYRX

11/13/2026: CYRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Cryoport Inc is a specialized life sciences tools and services company providing integrated temperature-controlled supply chain solutions, biostorage, and cryogenic equipment primarily for cell and gene therapies. The company's main business strengths include its proprietary Cryoportal tracking platform, a global service network, and market leadership in cryogenic storage systems through MVE. Its primary growth opportunity lies in supporting the expanding commercial pipeline of regenerative medicine treatments. However, execution risks remain around achieving sustained profitability and navigating fluctuating biotech funding cycles. The stock suits growth investors willing to tolerate volatility while monitoring clinical trial progress and operating margin improvements.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitCryoport offers direct exposure to the high-growth secular tailwinds of commercial cell and gene therapy pipelines.
Momentum investorStrong fit while signal remains positiveThe stock frequently reacts positively to clinical trial expansion milestones and upward revenue guidance revisions when market momentum is favorable.
Value investorWeak fitThe company is currently prioritizing operational scale over near-term bottom-line earnings and positive net income.
Dividend investorWeak fitCryoport does not pay dividends, retaining all cash flows to fund internal development and expansion.
Low-risk investorWeak fitHigh share price volatility and exposure to early-stage biotechnology financing cycles introduce elevated risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences notable price swings driven by macro biotech funding sentiment and quarterly clinical milestone updates.
Valuation riskMedium / highValuation multiples depend heavily on long-term growth assumptions for the regenerative medicine sector.
Competition risk (specialized cold-chain and life sciences tools providers)MediumLarger life sciences tools enterprises could expand into integrated cryologistics, increasing pricing pressure.
Business qualityMedium / highCryoport maintains a defensible niche with specialized infrastructure, though profitability is still scaling.
Dividend incomeLow / noneIncome-focused investors receive zero dividend yield as capital is reinvested into the business.
Execution riskMedium / highSuccessfully scaling global supply chain operations and integrating past acquisitions is critical to achieving sustained profitability.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.01B USD
Price to earnings Ratio -
1Y Target Price 22.33
Price to earnings Ratio -
1Y Target Price 22.33
Volume (30-day avg) 1.1M shares
Beta 1.87
52 Weeks Range 7.61 - 21.78
Updated Date 11/15/2026
52 Weeks Range 7.61 - 21.78
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.9

Sector & Industry Intelligence

Sector

Industrials

Constructive
Sentiment
Bullish
Momentum
BUY Breadth Improving
BUY participation
39.5%
Active BUY / eligible
30 / 76
30-Day BUY Count Change
+12
Market state
Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Integrated Freight & Logistics

BUY participation
0.0%
Active BUY / eligible
0 / 2
30-Day BUY Count Change
0

Eligible universe: 2 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -25.62%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CYRX receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CYRX has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+178.6%) and strong profitability (net margin 44.4%) are partially offset by weak cash generation (FCF margin -15.9%), negative revenue growth (-24.5%), modest insider ownership of 4.74%.

Financial Health Rating

★★★★★
CYRX's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 33.6%). Operating efficiency is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CYRX's strongest growth driver at +178.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+16.4%, solid) is also solid, while revenue growth (-24.5%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 92.6% and approximately 90.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.74% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.33%
Cadian Capital Management LP 5.77%
Arnhold & S. Bleichroeder Advisers, LLC 5.02%
Assenagon Asset Management SA 4.55%
Morgan Stanley - Brokerage Accounts 4.50%

Unit Economics (Per $1K Revenue)

★★★★★
CYRX generates approximately $471 of gross profit, $-209 of operating income, and $-159 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and solid capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 343.40%

Quantitative Style Profile

★★★★★
CYRX has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Life Sciences ServicesRevenues from specialized BioLogistics shipping, chain-of-identity tracking via the Cryoportal, and biostorage/bioservices.This is the core service engine that generates recurring revenue each time a clinical trial or commercial therapy is transported.
Life Sciences ProductsSales of MVE cryogenic freezers, dewars, and temperature-monitoring hardware to research labs and biopharma clients.Provides equipment sales that complement logistics services and capture upfront capital spending in life science facilities.
Geographic Exposure (Americas, EMEA, APAC)Global distribution spanning major life science hubs across North America, Europe, the Middle East, Africa, and Asia-Pacific.Offers diversified international exposure to global biopharmaceutical R&D and clinical trial activity.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 76.34
Enterprise Value 894.12M
Price to Sales(TTM) 5.24
Enterprise Value 894.12M
Price to Sales(TTM) 5.24
Enterprise Value to Revenue 4.65
Enterprise Value to EBITDA -13
Shares Outstanding 50.65M
Shares Floating 46.01M
Shares Outstanding 50.65M
Shares Floating 46.01M
Percent Insiders 4.74
Percent Institutions 92.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.